High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H

Imai,Hiroo; Kato,Shunsuke; Sakamoto,Yasuhiro; Kakudo,Yuichi; Shimodaira,Hideki; Ishioka,Chikashi

doi:10.3892/or.2013.2953

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H

Authors:
- Hiroo Imai
- Shunsuke Kato
- Yasuhiro Sakamoto
- Yuichi Kakudo
- Hideki Shimodaira
- Chikashi Ishioka
View Affiliations

Affiliations: Department of Clinical Oncology, IDAC, Tohoku University, Sendai, Miyagi 980-8575, Japan
Published online on: December 30, 2013 https://doi.org/10.3892/or.2013.2953
Pages: 1043-1050
Copyright: © Imai et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The TP53 mutation (R175H) is one of the most common mutations in human cancer. It is a highly attractive strategy for cancer therapy to find the genes that lead the R175H-expressing cancer cells. The aim of this study was to identify the synthetic sick/lethal gene interacting with R175H. Using lentiviral bar-coded comprehensive shRNA library and a tetracycline-inducible R175H expressed in the SF126 human glioblastoma cell line (SF126-tet-R175H), we conducted high-throughput screening to identify the candidate genes that induce synthetic sickness/lethality in R175H-expressing cells. We identified 906 candidate gene suppressions that may lead to accelerated cell growth inhibition in the presence of R175H. Inhibitor of differentiation 1 (ID1) was one of the candidate genes, and its suppression by siRNA resulted in the acceleration of growth inhibition in cell lines both transiently and endogenously expressing R175H but not in TP53-null cell lines or other common p53 mutants (such as R273H). Flow cytometry analysis showed that ID1 suppression resulted in G1 arrest, and the arrest was accelerated by the expression of R175H. ID1 is a synthetic sick/lethal gene that interacts with R175H and is considered to be a novel molecular target for cancer therapy in R175H-expressing cells.

View Figures

View References

1	Molenaar JJ, Ebus ME, Geerts D, et al: Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA. 106:12968–12973. 2009. View Article : Google Scholar : PubMed/NCBI
2	Canaani D: Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br J Cancer. 100:1213–1218. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 5:689–698. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bandyopadhyay N, Ranka S and Kahveci T: Sslpred: predicting synthetic sickness lethality. Pac Symp Biocomput. 7–18. 2012.
5	Luo J, Emanuele MJ, Li D, et al: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 137:835–848. 2009. View Article : Google Scholar : PubMed/NCBI
6	Scholl C, Fröhling S, Dunn IF, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 137:821–834. 2009. View Article : Google Scholar : PubMed/NCBI
7	Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434:917–921. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kaye SB, Lubinski J, Matulonis U, et al: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 30:372–379. 2012. View Article : Google Scholar
9	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
10	Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
11	Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:823–827. 1997. View Article : Google Scholar : PubMed/NCBI
12	Sakaguchi K, Herrera JE, Saito S, et al: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
13	Soussi T, Dehouche K and Béroud C: p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat. 15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI
14	Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
15	Soussi T, Ishioka C, Claustres M and Béroud C: Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer. 6:83–90. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kato S, Han SY, Liu W, et al: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
17	Olive KP, Tuveson DA, Ruhe ZC, et al: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 119:847–860. 2004. View Article : Google Scholar : PubMed/NCBI
18	Lang GA, Iwakuma T, Suh YA, et al: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 119:861–872. 2004. View Article : Google Scholar : PubMed/NCBI
19	Song H, Hollstein M and Xu Y: p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 9:573–580. 2007. View Article : Google Scholar : PubMed/NCBI
20	Liu G, McDonnell TJ, Montes de Oca Luna R, et al: High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA. 97:4174–4179. 2000. View Article : Google Scholar : PubMed/NCBI
21	Watanabe G, Kato S, Nakata H, Ishida T, Ohuchi N and Ishioka C: αB-crystallin: a novel p53-target gene required for p53-dependent apoptosis. Cancer Sci. 100:2368–2375. 2009.
22	Shiraishi K, Kato S, Han SY, et al: Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 279:348–355. 2004. View Article : Google Scholar : PubMed/NCBI
23	Dong Z, Wei F, Zhou C, et al: Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol. 47:27–32. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kakudo Y, Shibata H, Otsuka K, Kato S and Ishioka C: Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 65:2108–2114. 2005. View Article : Google Scholar : PubMed/NCBI
25	Ling MT, Wang X, Zhang X and Wong YC: The multiple roles of Id-1 in cancer progression. Differentiation. 74:481–487. 2006. View Article : Google Scholar : PubMed/NCBI
26	Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990. View Article : Google Scholar : PubMed/NCBI
27	Sun XH: Constitutive expression of the Id1 gene impairs mouse B cell development. Cell. 79:893–900. 1994. View Article : Google Scholar : PubMed/NCBI
28	Jen Y, Weintraub H and Benezra R: Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev. 6:1466–1479. 1992. View Article : Google Scholar : PubMed/NCBI
29	Kreider BL, Benezra R, Rovera G and Kadesch T: Inhibition of myeloid differentiation by the helix-loop-helix protein Id. Science. 255:1700–1702. 1992. View Article : Google Scholar : PubMed/NCBI
30	Rothschild SI, Kappeler A, Rastchiller D, et al: The stem cell gene ‘inhibitor of differentiation 1’ (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer. 71:306–311. 2011.
31	Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW and Wong YC: Id-1 expression promotes cell survival through activation of NF-κB signalling pathway in prostate cancer cells. Oncogene. 22:4498–4508. 2003.PubMed/NCBI
32	Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
33	Roger L, Jullien L, Gire V and Roux P: Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 123:1295–1305. 2010. View Article : Google Scholar : PubMed/NCBI
34	Yan W and Chen X: Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem. 284:12178–12187. 2009. View Article : Google Scholar : PubMed/NCBI
35	Liu DP, Song H and Xu Y: A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene. 29:949–956. 2010. View Article : Google Scholar : PubMed/NCBI